Oncocross Co., Ltd. (KOSDAQ:382150)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Discovery and Development of Drugs		91.52M	150.25M	100.00M	90.00M
Discovery and Development of Drugs Growth		-39.08%	50.25%	11.11%	-
Total		91.52M	150.25M	100.00M	90.00M
Total Growth		-39.08%	50.25%	11.11%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
South Korea		91.52M	150.25M	100.00M	90.00M
South Korea Growth		-39.08%	50.25%	11.11%	-
Total		91.52M	150.25M	100.00M	90.00M
Total Growth		-39.08%	50.25%	11.11%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 1, 2026

Data Sources Report a data error